Results from the study showed that the antibody reduced tumour growth and reduced skeletal lesions, both independently and in combination therapy.

“Our goal is effective anticancer therapeutic strategies that can reduce breast tumour growth in nonskeletal and skeletal sites”, says Niaz Mahmood, lead author on the study. “We are one step closer now.”

About the study

Mahmood, N., Arakelian, A., Khan, H.A., Tanvir, I., Mazar, A.P., and Rabbani, S.A. uPAR antibody (huATN-658) and Zometa reduce breast cancer growth and skeletal lesions. Bone Res 8, 18 (2020).

The study was supported by a grant from the Canadian Institutes of Health Research.